common.study.topics.clinical

Buprenorphine for Probationers and Parolees

common.study.values.description

Buprenorphine for Probationers and Parolees: Bridging the Gap Into Treatment

This five-year study will evaluate the effectiveness of the administration of buprenorphine bridge treatment (BBT) to probationers and parolees compared to treatment as usual (TAU), which consists of referral to a community buprenorphine treatment program.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Patients and healthy individuals accepted common.study.methods.is-healthy-no

Drug - Buprenorphine/Naloxone

Participants will begin buprenorphine pharmacotherapy using the MedicaSafe buprenorphine dispensing device immediately after an on-site intake at a community supervision office and continue such treatment until they are transitioned to community buprenorphine treatment

Treatment as usual

Participants will receive a referral to buprenorphine treatment in the community

participant.views.study.view.additional

participant.views.study.view.scientific-title

Buprenorphine for Probationers and Parolees: Bridging the Gap Into Treatment

common.study.values.clinical-trial-id

NCT03616236

participant.views.study.view.id

en5ZWd